A key secondary endpoint is the time to an IPF exacerbation, hospitalisation for breathing problems, or death, which if positive could differentiate the drug from current therapies. Boehringer has ...

Introduction Interstitial lung disease (ILD) patients may develop a progressive phenotype usually characterised by ...

Boehringer's drug cut the decline by 45 to 68 percent, depending on the patient group and also reduced the rate of IPF exacerbations. The NICE backing is good news for Boehringer as it competes in ...